These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19716955)

  • 1. Rivaroxaban versus enoxaparin after total knee arthroplasty.
    Gómez-Outes A; Suárez-Gea ML; Blázquez-Pérez A; Pozo-Hernández C; Vargas-Castrillón E
    Lancet; 2009 Aug; 374(9691):682; author reply 683. PubMed ID: 19716955
    [No Abstract]   [Full Text] [Related]  

  • 2. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
    Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban versus enoxaparin after total knee arthroplasty.
    Longo UG; Maffulli N; Denaro V
    Lancet; 2009 Aug; 374(9691):681-2; author reply 683. PubMed ID: 19716953
    [No Abstract]   [Full Text] [Related]  

  • 5. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban versus enoxaparin after total knee arthroplasty.
    Raju NC; Dimmitt S; Eikelboom JW
    Lancet; 2009 Aug; 374(9691):681; author reply 683. PubMed ID: 19716954
    [No Abstract]   [Full Text] [Related]  

  • 7. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban versus enoxaparin after total knee arthroplasty.
    Stief T
    Lancet; 2009 Aug; 374(9691):681; author reply 683. PubMed ID: 19716952
    [No Abstract]   [Full Text] [Related]  

  • 9. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    Cao YB; Zhang JD; Shen H; Jiang YY
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1099-108. PubMed ID: 20812009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
    Lassen MR; Gent M; Kakkar AK; Eriksson BI; Homering M; Berkowitz SD; Turpie AG
    J Bone Joint Surg Br; 2012 Nov; 94(11):1573-8. PubMed ID: 23109641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Turpie AG; Lassen MR; Davidson BL; Bauer KA; Gent M; Kwong LM; Cushner FD; Lotke PA; Berkowitz SD; Bandel TJ; Benson A; Misselwitz F; Fisher WD;
    Lancet; 2009 May; 373(9676):1673-80. PubMed ID: 19411100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
    Turpie AG; Fisher WD; Bauer KA; Kwong LM; Irwin MW; Kälebo P; Misselwitz F; Gent M;
    J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.
    Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P
    Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban (Xarelto)--a new oral anticoagulant.
    Med Lett Drugs Ther; 2011 Aug; 53(1371):65-7. PubMed ID: 21860366
    [No Abstract]   [Full Text] [Related]  

  • 17. Rivaroxaban for thromboprophylaxis.
    Lotke PA
    N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009675
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).
    Rosencher N; Llau JV; Mueck W; Loewe A; Berkowitz SD; Homering M
    Acta Anaesthesiol Scand; 2013 May; 57(5):565-72. PubMed ID: 23336294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.